ABSTRACT
Rhodium II citrate was tested in mice for acute toxicity, antitumoral activity against Ehrlich ascites carcinoma and inhibition of DNA synthesis by Ehrlich tumor, malignant adrenocortical cells (Y-1) and normal adrenocortical cells (AR-1)_. At ip doses up to 260 mg/Kg, the compound had no toxic effects for up to 14 days. The same total dose given over 4 days significantly increased the survial rat of mice bearing Ehrlich ascites cells. Thymidine incorporation by Ehrlkich tumor, Y-1 cells in vitro was inhibited 50% by a.1 to 0.2 mM concentrations of the compound. We conclude that the increase survival of the tumor-bearing mice was due at least in part to the inhibition of DNA synthesis with a consequet reduction of cell division and tumor growth
Subject(s)
Mice , Animals , Carcinoma, Ehrlich Tumor/pathology , Citrates/pharmacology , Rhodium/pharmacology , Carcinoma, Ehrlich Tumor/mortality , Citrates/toxicity , DNA/biosynthesis , Rhodium/toxicityABSTRACT
o citrato de ródio II sintetizado na procura de complexos de ródio com atividade anti-tumoral e baixa toxicidade. Näo foram observados mortes ou outros sinais de toxicidade após injeçäo de 260 mg/Kg de citrato de ródio II, intra-peritonial em camundongos observados durante 14 dias. A substância provaca um quadro inflamatório que se caracteriza por edema persistente por 24 horas, quando injetada na pata de ratos. Injetada na cavidade peritonial há aumento de neutrófilos segmentados no exudato peritoneal bem como aumento significativo no número de macrófagos espraiados